Pasar al contenido principal

Toward a complete simulation environment for complement-associated pathologies: Physiology-inspired pharmacokinetics/pharmacodynamics, digital twins, and artificial intelligence-assisted digital pathology (TwinKidz)

CPP2022-009838

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos en Colaboración Público-Privada
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ABVANCE BIOTECH SL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Systems immunology: When systems biology meets immunology

  • Alfonso-González, Lucía
  • Fernández, Francisco J
  • Vega, María Cristina
The immune system is an intricate network of cells, proteins, and signaling pathways that coordinate protective responses and, when dysregulated, drive immune-related diseases. Understanding this complexity increasingly relies on systems-based mathematical and computational approaches, which integrate multi-omics data, mechanistic models, and artificial intelligence to reveal the emergent behavior of immune networks. In this mini-review, we discuss the central methodological pillars of systems immunology, including Network Pharmacology, artificial intelligence, and quantitative systems pharmacology. We highlight illustrative applications spanning autoimmune, inflammatory, and infectious diseases, and describe how these methods are used to identify biomarkers, optimize therapies, and guide drug discovery. Finally, we examine current challenges and future directions, including data quality, model validation, and regulatory considerations, which must be addressed to translate systems immunology into clinical impact. This integrated perspective aims to guide both method developers and translational researchers, emphasizing the growing role of computational modeling in next-generation immunology and therapeutic innovation., The author(s) declare financial support was received for the research and/or publication of this article. This work was funded by the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 (MCV) and CPP2022-009838 (FJF and MCV); grant S2022/BMD-7278 of the Regional Government of Madrid (MCV); the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (MCV); and the Instituto de Salud Carlos III (ISCIII) grant PI24/00925 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T) (MCV). LA-G was supported by an Industrial PhD grant (IND2019/BMD-17219) from the Regional Government of Madrid (FJF and MCV). The funders had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative (PROA) through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3 mutations and poor pegcetacoplan response in paroxysmal nocturnal hemoglobinuria

  • Rodríguez de Córdoba, Santiago
  • Reparaz, Andrea
  • González Sanz, Silvia
  • Fernández, Francisco J.
  • Vega, María Cristina
  • Varela, Enrique Colado
  • Lada Colunga, Alejandro
  • Vallejo Llamas, Juan Carlos
  • Gonzalez-Rodríguez, Ana Pilar
Paroxysmal nocturnal hemoglobinuria (PNH) is treated with complement inhibitors, yet incomplete responses remain a challenge. Terminal inhibition with eculizumab prevents intravascular hemolysis but often leaves residual extravascular hemolysis, while proximal inhibitors such as pegcetacoplan mitigate extravascular hemolysis though intravascular hemolysis may persist. Understanding resistance mechanisms is critical to guide therapy., The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by a Spanish grant from the Regional Government of Madrid (S2022/BMD-7278), the Instituto de Salud Carlos III (PI23/01576 and PI24/00925) co-funded by the European Union, the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 and CPP2022-009838, Fundación Xti Xtod@s, the Fundación LAIR, the Fundación Alimerka and the Government of the Principality of Asturias through the Agency for Science, Business Competitiveness and Innovation of the Principality of Asturias and co-funded by the European Union, through the Grants for Research Groups of Organizations of the Principality of Asturias for Fiscal Year 2024, with file number IDE/2024/000745. It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T). We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative (PROA) through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C-model: A comprehensive enhanced pharmacokinetic/pharmacodynamic simulation environment targeting the complement system

  • Alfonso-González, Lucía
  • Vega, María Cristina
  • Fernández, Francisco J.
Recently, there has been increased research on treatments that modulate the complement system because of its significance in many diseases. However, managing patients with complement-related diseases is challenging owing to the different responses to treatments because of the heterogeneity of the aetiology of the different diseases, which may affect different proteins of the complement activation cascade. This study addresses these challenges using a comprehensive computational model, C-model., LAG acknowledges the support of the PhD program in Medicinal Chemistry of the Universidad Complutense de Madrid (UCM). This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grant RTI2018-102242-B-I00 (MCV); the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 (MCV) and CPP2022-009838 (FJF and MCV); grants S2017/BMD-3673 and S2022/BMD-7278 of the Regional Government of Madrid (MCV); the European Commission – NextGenerationEU through CSIC's Global Health Platform (‘PTI Salud Global’) (SGL2103020) (MCV); and the CSIC Special Intramural Grant PIE-201620E064 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T) (MCV). We also acknowledge the CSIC Network of Rare Diseases (RER-CSIC). LAG was supported by an Industrial PhD grant (IND2019/BMD-17219) from the Regional Government of Madrid (FJF and MCV)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases

  • Fernández, Francisco J.
  • Alfonso-González, Lucía
  • Praga, Manuel
  • Mikkelsen, Kaare
  • Vega, María Cristina
Eculizumab, a humanized monoclonal antibody targeting the complement protein C5, is highly efficient in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. However, recent reports have highlighted a subset of patients who show inadequate treatment response, prompting dose escalation or interval shortening. The serum concentration required for sustained inhibition of the complement lytic pathway remains uncertain, and the commonly cited 50-100 µg/ml range is not grounded in robust pharmacokinetic-pharmacodynamic data. Using publicly available clinical data digitized from four rare indications, we trained machine-learning supervised classifiers to predict complete C5 inhibition as a function of serum eculizumab concentration, identifying logistic regression on log-transformed concentration as the best and mechanistically appropriate model on real data. We then examined whether augmenting the real training data with high-fidelity synthetic data improves the resulting estimate. Although augmentation did not significantly change balanced accuracy, it reduced the confidence interval for the effective concentration by roughly 12-fold (a 92% reduction). The augmentation-stabilized estimate of the concentration associated with complete C5 inhibition was approximately 310.8-335.2 µg/ml (real-data-only estimate 338 µg/ml, 95% CI 275-454). These data-driven, hypothesis-generating results indicate that current maintenance targets aimed at near-complete C5 suppression may be substantially underestimated and that faithful synthetic augmentation can improve the precision of model-based pharmacological estimates in rare diseases; prospective validation in independent cohorts is required before any clinical application., The author(s) declared that financial support was received for this work and/or its publication. This work was funded by the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 (MV) and CPP2022-009838 (FF); grant S2022/BMD-7278 from the Regional Government of Madrid (MV); the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (MV); and the Instituto de Salud Carlos III (ISCIII) grant PI24/00925 (MV). It was also supported by the Research Network on Complement in Health and Disease (RED2022-134750-T) (MV). LA-G received support through an Industrial PhD grant (IND2019/BMD-17219) from the Regional Government of Madrid (FF and MV)., Peer reviewed